Advertisement
U.S. markets closed

AVITA Medical, Inc. (51KA.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
15.10+0.50 (+3.42%)
At close: 04:51PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.60
Open15.10
Bid14.70 x N/A
Ask15.10 x N/A
Day's Range15.10 - 15.10
52 Week Range8.60 - 18.70
Volume200
Avg. Volume17
Market Cap404.999M
Beta (5Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-1.29
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 51KA.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Simply Wall St.

      This AVITA Medical Insider Increased Their Holding By 250% Last Year

      Viewing insider transactions for AVITA Medical, Inc.'s ( NASDAQ:RCEL ) over the last year, we see that insiders were...

    • GlobeNewswire

      AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement

      VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced it has submitted its response to the U.S. Food and Drug Administration (FDA) for additional information requested in connection to its premarket approval (PMA) supplement for RECELL GO™. This submission resumes the substantive interactive review process u

    • GlobeNewswire

      AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference

      VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O’Toole, Chief Financial Officer, will present at TD Cowen’s 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 9:50 a.m. Eastern Time. A live audio webcast of the presentation will be available under the Events & Presentations se